Sign Up Today and Learn More About Amphista Therapeutics Stock
Invest in or calculate the value of your shares in Amphista Therapeutics or other pre-IPO companies through EquityZen's platform.
Amphista Therapeutics Stock (AMTH)
Amphista Therapeutics operates as a biopharmaceutical company.
About Amphista Therapeutics Stock
Founded
2017
Industries
Travel and Tourism, Manufacturing, Space
Amphista Therapeutics Press Mentions
Stay in the know about the latest news on Amphista Therapeutics
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
biospace • Oct 28, 2025
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
globenewswire • Oct 28, 2025
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
globenewswire • Oct 27, 2025
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
biospace • Oct 23, 2025
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
biospace • Oct 16, 2025
Amphista Therapeutics Management
Leadership team at Amphista Therapeutics
Chairman
Joshua T. Brumm
Chief Scientific Officer
Ian Churcher
Join now and verify your accreditation status to gain access to:
- Amphista Therapeutics Current Valuation
- Amphista Therapeutics Stock Price
- Amphista Therapeutics Management
- Available deals in Amphista Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Amphista Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Amphista Therapeutics Revenue and Financials
- Amphista Therapeutics Highlights
- Amphista Therapeutics Business Model
- Amphista Therapeutics Risk Factors
- Amphista Therapeutics Research Report from SACRA Research
Trading Amphista Therapeutics Stock
How to invest in Amphista Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Amphista Therapeutics through EquityZen funds. These investments are made available by existing Amphista Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Amphista Therapeutics stock?
Shareholders can sell their Amphista Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
